|
Baseline characteristics of 272 patients who received combination IFN-α and RBV therapy for HCV |
|
| Demographics |
|
|
|
|
| Mean age (years) |
42 ± 8 |
| Males |
150 (55%) |
| Caucasians |
204 (75%) |
| Asians |
22 (8%) |
| Weight (kg) |
79 ± 18 |
| HCV Genotype |
|
|
|
|
| 1 |
136 (50%) |
| 2 |
22 (8%) |
| 3 |
103 (38%) |
| 4 |
11 (4%) |
| Liver Function Tests (RR) |
|
|
|
|
| Albumin (36–48 g/L) |
41 ± 2 |
| Serum Bilirubin (2–20 μmol/L) |
15 ± 6 |
| Alanine Aminotransferase (< 45 U/L) |
133 ± 58 |
| γ-Glutamyl Transpeptidase (1–30 U/L) |
98 ± 46 |
| Prothrombin time (11–18 seconds) |
15 ± 3 |
| Haematological Parameters (RR) |
|
|
|
|
| Haemoglobin (115–165 g/L) |
142 ± 16 |
| White cell counts (4.0–11.0 × 106/mL) |
7.1 ± 2.0 |
| Platelets (150–400 × 109/mL) |
168 ± 49 |
Tran et al. BMC Endocrine Disorders 2005 5:8 doi:10.1186/1472-6823-5-8 |
|